NASH and Hepatocellular Carcinoma (HCC)
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: 31 August 2024 | Viewed by 6466
Special Issue Editor
Special Issue Information
Dear Colleagues,
Caloric excess and sedentary lifestyle are growing health concerns that have led to a global epidemic of obesity and metabolic syndrome. Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of obesity and metabolic syndrome, is a major cause of liver disease worldwide and its prevalence is increasing in parallel with obesity and type 2 diabetes. This spectrum of NAFLD ranges from simple steatosis to nonalcoholic steatohepatitis (NASH) and cirrhosis, which ultimately leads to hepatocellular carcinoma (HCC), a leading cause of cancer-related deaths worldwide. Liver damage associated with NASH leads to a cycle of cell death, liver regeneration, and fibrosis, during which HCC precursor cells undergo malignant transformation, leading to cancer initiation. Several mechanisms have been proposed to underlie the progression of NASH to cirrhosis, and eventually HCC, including cell death, ER stress, mitochondrial dysfunction, inflammation, and oxidative stress. The mechanisms of progression of NASH, fibrosis, and HCC are far from being understood.
In this Special Issue, we aim to present a series of review and research articles that elucidate the progression in the diagnosis, prevention, and treatment of NASH and HCC, along with the many challenges that still remain. We welcome basic, translational, or clinical studies that contribute to our new understanding of disease progression from NASH and HCC as well as potential new therapies.
Dr. Feng He
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- NAFLD
- NASH
- HCC
- obesity
- inflammation
- immunotherapy
- stress
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.